Gene Expression Profiling in Uveal Melanoma: A Cutting-Edge Innovation in Ophthalmic Pathology

Pathologists are at the forefront of personalised medicine, using molecular tools to tailor diagnoses, prognoses, and treatments. In ophthalmic pathology, one of the most significant developments in recent years has been the integration of gene expression profiling (GEP) into the management of uveal melanoma, the most common primary intraocular malignancy in adults in the United Kingdom. Traditionally risk stratification has been based on tumour size, cell morphology, and mitotic activity. The development of GEP assays, particularly DecisionDx-UM, has significantly improved prognostic accuracy in uveal melanoma, paving the way for personalised care based on molecular tumour profiling.